Depression symptom dimensions as predictors of antidepressant treatment outcome: Replicable evidence for interest-activity symptoms

Psychological Medicine

Volumn 42, Issue 5, 2012, Pages 967-980

  Uher, R ^a   Perlis, R H ^b   Henigsberg, N ^c   Zobel, A ^d   Rietschel, M ^e   Mors, O ^f   Hauser, J ^g   Dernovsek, M Z ^h   Souery, D ⁱ   Bajs, M ^c   Maier, W ^d   Aitchison, K J ^a   Farmer, A ^a   McGuffin, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY OF BONN   (Germany)

^e CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h University Psychiatric Clinic   (Slovenia)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Antidepressant medication; depressive symptoms; dimensional classification; major depression; outcome prediction

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AFFECT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; EUROPE; FACTORIAL ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; AFFECT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; COGNITION; DEPRESSIVE DISORDER, MAJOR; EUROPE; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; NORTRIPTYLINE; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84859262307     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291711001905     Document Type: Article

References (57)

1. Beck AT, Ward CH, Mandelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Archives of General Psychiatry 4, 561-571.
2. Bjelland I, Lie SA, Dahl AA, Mykletun A, Stordal E, Kraemer HC (2009). A dimensional versus a categorical approach to diagnosis: anxiety and depression in the HUNT 2 study. International Journal of Methods in Psychiatric Research 18, 128-137.
3. Brown WA (2007). Treatment response in melancholia. Acta Psychiatrica Scandinavica 433, 125-129. (Pubitemid 46114847)
4. Bruhl AB, Kaffenberger T, Herwig U (2010). Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology 35, 521-533.
5. Carney MWP, Roth M, Garside RF (1965). The diagnosis of depressive syndromes and the prediction of E.C.T. response. British Journal of Psychiatry 111, 659-674.
6. Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E, Bullmore E (2007). Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biological Psychiatry 62, 407-414. (Pubitemid 47284016)
7. Deyi BA, Kosinski AS, Snapinn SM (1998). Power considerations when a continuous outcome variable is dichotomized. Journal of Biopharmaceutical Statistics 8, 337-352. (Pubitemid 28239876)
8. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK, Atkins DC, Dunner DL, Jacobson NS (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology 74, 658-670. (Pubitemid 44199118)
9. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH (2008). Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry 165, 342-351. (Pubitemid 351704490)
10. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF (1997). Major depressive subtypes and treatment response. Biological Psychiatry 42, 568-576. (Pubitemid 27425475)
11. Flett GL, Vredenburg K, Krames L (1997). The continuity of depression in clinical and nonclinical samples. Psychological Bulletin 121, 395-416. (Pubitemid 127705299)
12. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48, 851-855.
13. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Clinical Psychology 6, 278-296.
14. Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M (2008). Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Annals of Clinical Psychiatry 20, 209-218.
15. Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, Gortner E, Prince SE (1996). A component analysis of cognitive-behavioral treatment for depression. Journal of Consulting and Clinical Psychology 64, 295-304.
16. Joyce PR, Mulder RT, McKenzie JM, Luty SE, Cloninger CR (2004). Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depression and Anxiety 19, 180-186. (Pubitemid 38685535)
17. Korszun A, Moskvina V, Brewster S, Craddock N, Ferrero F, Gill M, Jones IR, Jones LA, Maier W, Mors O, Owen MJ, Preisig M, Reich T, Rietschel M, Farmer A, McGuffin P (2004). Familiality of symptom dimensions in depression. Archives of General Psychiatry 61, 468-474. (Pubitemid 38620845)
18. Kraemer HC, Kupfer DJ (2006). Size of treatment effects and their importance to clinical research and practice. Biological Psychiatry 59, 990-996. (Pubitemid 43849650)
19. Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S (2009). Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Research 169, 132-138.
20. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD (2007). Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. Journal of Consulting and Clinical Psychology 75, 267-276. (Pubitemid 47444731)
21. Mallinckrodt CH, Zhang L, Prucka WR, Millen BA (2010). Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacology Bulletin 43, 53-72.
22. McGrath PJ, Khan AY, Trivedi MH, Stewart JW, Morris DW, Wisniewski SR, Miyahara S, Nierenberg AA, Fava M, Rush JA (2008). Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. Journal of Clinical Psychiatry 69, 1847-1855.
23. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF (2000). A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. American Journal of Psychiatry 157, 344-350. (Pubitemid 30145918)
24. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA (2009). Exercise for depression. Cochrane Database of Systematic Reviews (4), CD004366.
25. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389. (Pubitemid 9136500)
26. Nelson JC (2010). Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebocontrolled trials. Depression and Anxiety 27, 12-18.
27. Parker G (2007). Defining melancholia: the primacy of psychomotor disturbance. Acta Psychiatrica Scandinavica. Supplementum (433), 21-30. (Pubitemid 46114836)
28. Parker G, Fletcher K, Hyett M, Hadzi-Pavlovic D, Barrett M, Synnott H (2009). Measuring melancholia: the utility of a prototypic symptom approach. Psychological Medicine 39, 989-998.
29. Parker G, Wilhelm K, Mitchell P, Roy K, Hadzi-Pavlovic D (1999). Subtyping depression: testing algorithms and identification of a tiered model. Journal of Nervous and Mental Disease 187, 610-617. (Pubitemid 29489504)
30. Paykel ES, Rowan PR, Parker RR, Bhat AV (1982). Response to phenelzine and amitriptyline in subtypes of outpatient depression. Archives of General Psychiatry 39, 1041-1049. (Pubitemid 12020987)
31. Perlis RH, Patrick A, Smoller JW, Wang PS (2009). When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34, 2227-2236.
32. Perry PJ (1996). Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders 39, 1-6. (Pubitemid 26235318)
33. Prisciandaro JJ, Roberts JE (2005). A taxometric investigation of unipolar depression in the National Comorbidity Survey. Journal of Abnormal Psychology 114, 718-728. (Pubitemid 41747007)
34. Prisciandaro JJ, Roberts JE (2009). A comparison of the predictive abilities of dimensional and categorical models of unipolar depression in the National Comorbidity Survey. Psychological Medicine 39, 1087-1096.
35. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GJ, Massung B, Miller AH (2009). Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biological Psychiatry 65, 296-303.
36. Rasmussen NA, Schroder P, Olsen LR, Brodsgaard M, Unden M, Bech P (2005). Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nordic Journal of Psychiatry 59, 173-178. (Pubitemid 40946275)
37. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996). The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychological Medicine 26, 477-486. (Pubitemid 26142491)
38. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573-583. (Pubitemid 37289444)
39. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905-1917. (Pubitemid 44807782)
40. Russell JM, Koran LM, Rush J, Hirschfeld RM, Harrison W, Friedman ES, Davis S, Keller M (2001). Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depression and Anxiety 13, 18-27. (Pubitemid 32537090)
41. Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB (2005). Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Archives of General Psychiatry 62, 513-520. (Pubitemid 40628880)
42. Siegle GJ, Steinhauer SR, Friedman ES, Thompson WS, Thase ME (2011). Remission prognosis for cognitive therapy for recurrent depression using the pupil: utility and neural correlates. Biological Psychiatry 69, 726-733.
43. Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, Nierenberg AA, Trivedi MH, Balasubramani GK, Warden D, Lesser I, John RA (2010). Do atypical features affect outcome in depressed outpatients treated with citalopram? International Journal of Neuropsychopharmacology 13, 15-30.
44. Streiner DL (2002). Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Canadian Journal of Psychiatry 47, 262-266. (Pubitemid 34614684)
45. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and metaanalysis. Archives of General Psychiatry 63, 1217-1223. (Pubitemid 44708080)
46. Thase ME (2009). Atypical depression: useful concept, but it's time to revise the DSM-IV criteria. Neuropsychopharmacology 34, 2633-2641.
47. Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ (2006). Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectrums 11, 93-102.
48. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28-40. (Pubitemid 43050100)
49. Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A, Maier W, Henigsberg N, Kalember P, Rietschel M, Placentino A, Mendlewicz J, Aitchison KJ, McGuffin P, Farmer A (2011). Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders 132, 112-120.
50. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, Henigsberg N, Perez J, Mendlewicz J, Janzing JG, Zobel A, Skibinska M, Kozel D, Stamp AS, Bajs M, Placentino A, Barreto M, McGuffin P, Aitchison KJ (2008). Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine 38, 289-300. (Pubitemid 351156595)
51. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P (2009a). Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry 194, 252-259.
52. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, Henigsberg N, Souery D, Placentino A, Perroud N, Dernovsek MZ, Strohmaier J, Larsen ER, Zobel A, Leszczynska-Rodziewicz A, Kalember P, Pedrini L, Linotte S, Gunasinghe C, Aitchison KJ, McGuffin P, Farmer A (2009b). Body weight as a predictor of antidepressant efficacy in the GENDEP project. Journal of Affective Disorders 118, 147-154.
53. Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison KJ, Farmer A, McGuffin P (in press). Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression. Journal of Clinical Psychiatry.
54. Uher R, Muthen B, Souery D, Mors O, Jaracz J, Placentino A, Petrovic A, Zobel A, Henigsberg N, Rietschel M, Aitchison KJ, Farmer A, McGuffin P (2010). Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine 40, 1367-1377.
55. Veen G, van Vliet IN, Derijk RH, Giltay EJ, van Pelt J, Zitman FG (2011). Basal cortisol levels in relation to dimensions and DSM-IV categories of depression and anxiety. Psychiatry Research 185, 121-128.
56. Wardenaar KJ, Vreeburg SA, van Veen T, Giltay EJ, Veen G, Penninx BW, Zitman FG (2011). Dimensions of depression and anxiety and the hypothalamo-pituitary-adrenal axis. Biological Psychiatry 69, 366-373.
57. Wing JK, Sartorius N, Ustin TB (1998). Diagnosis and Clinical Measurement in Psychiatry. A Reference Manual for SCAN. World Health Organization: Geneva.